Pharmacological treatment during AMI and in secondary prevention: the scientific evidence
| STUDIES | DRUGS | No. PATIENTS | FOLLOW-UP | VAR. | P |
|---|---|---|---|---|---|
| During infarction and 4-6 weeks after | |||||
| GISSI-3 (1996) [35] | NITROGLICERINE (iv & transdermal) |
19,394 | 42 DAYS | -6% | 0.28 |
| ISIS 4 (1995) [47] | ISOSORBIDE MN | 58,050 | 35 DAYS | -3% | 0.30 |
| META-ANALYSES | No. STUDIES | No. PATIENTS | VAR | P | |
| During infarction | |||||
| YUSUF (1988) [101] | 10 | 2,000 | -35% | < 0.01 | |
| ISIS-4 (1995) [47] | 22 | 81,908 | -6% | 0.03 | |
ACC/AHA GUIDELINESGenerally the results are not in favour of long-term, routine use in pts. with simple MI. They may be used in CHF, in extensive transmural AMI and in reinfarction |
ANMCO-SIC CLINICAL GUIDELINESThere are no proofs on the utility of routine usage. Use only in pts. with angina, silent ischemia or with clinical signs of CHF and together with other vasodilators |